38
G.G. Mohamed et al. / Journal of Molecular Structure 999 (2011) 29–38
ATPases. Mn(II) can also replace Mg(II) as the activating ion for a
number of Mg(II)-dependent enzymes, although some enzyme
activity is usually lost [40]. Sometimes such enzyme metal prefer-
ences vary among closely related species: for example, the reverse
transcriptase enzyme of lentiviruses like HIV, SIV and FIV is typically
dependent on Mg(II), whereas the analogous enzyme for other retro-
viruses prefers Mn(II) [41]. Also according to the chelation theory
[38], the difference in activity between the two metal ions (Mn(II)
had d5 and Zn(II) had d10 configurations) can be attributed to the dif-
ference in probability of the d orbitals to overlap with the ligand
orbitals. Also it could be due to the difference in electronegativity,
size of the metal ion and the intermediate complex formation.
Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
References
[1] A. Garoufis, J. Hatiris, N. Hadjiliadis, J. Inorg. Biochem. 41 (1991) 195–
203.
[2] F.J. Pesch, H. Prent, B. Lippert, Inorg. Chim. Acta 169 (1990) 195–200.
[3] R.P. Rabindra, K. Sudhakar, Indian J. Chem. A29 (1990) 1182.
[4] R.P. Rabindra, R.M. Raviprakash, Indian J. Chem. A30 (1991) 1182.
[5] H. Sigel, B.E. Fisher, S. Farkas, Inorg. Chem. 22 (1983) 925–934.
[6] M. Sabat, K.A. Satyashur, M. Sundaralingam, J. Am. Chem. Soc. 105 (1983)
976.
[7] M.V.N. de Souza, M.V. de Almeida, Curr. Med. Chem. 10 (2003) 21–39.
[8] I. Turel, Coord. Chem. Rev. 232 (2002) 27–47.
5.2. Cytotoxic activity
[9] M. Ruiz, R. Ortiz, L. Perelló, S. García-Granda, M.R. Díaz, Inorg. Chim. Acta 217
(1994) 149–154.
[10] M. Ruiz, L. Perelló, J. Server-Carrió, R. Ortiz, S. García-Granda, M.R. Diaz, E.
Cantón, J. Inorg. Biochem. 69 (1998) 231–239.
The LFX drug, glycine and all their ternary metal complexes were
tested for their activity against breast cancer cell line (MCF7) by
using 100 lg/ml drug concentration. From these results, it is clear
[11] B. Macias, M.V. Villa, M. Sastre, A. Castiñeiras, J. Borrás, J. Pharm. Sci. 91 (2002)
2416–2423.
that LFX, [Mn(LFX)(Gly)(H2O)2]ꢀCl, [Co(LFX)(Gly)(H2O)2]ꢀCl, [Ni
(LFX)(Gly)(H2O)2]ClꢀH2O, [Cu(LFX)(Gly)(H2O)2]Clꢀ2H2O and [Zn
(LFX)(Gly)(H2O)2]ꢀCl were found to be very active against breast can-
cer cells with inhibition ratio values between 70% and 85.5%, while
other complexes utilized in this work had been shown to be inactive
(less than 70% inhibition). It is clear that a pattern of activity can be
determined using different drug concentrations (Table 7). LFX,
[Mn(LFX)(Gly)(H2O)2]ꢀCl, [Co(LFX)(Gly)(H2O)2]ꢀCl and [Zn(LFX)
(Gly)(H2O)2]ꢀCl were found to be very active with IC50 values 14,
11.2, 13 and 16.8, respectively, while glycine and other complexes
had been shown to be inactive at lower concentration than
[12] Z.H. Chohan, C.T. Supuran, A. Scozzafava, J. Enzyme Inhib. Med. Chem. 20
(2005) 303–307.
[13] Z.H. Chohan, H. Pervez, A. Rauf, C.T. Supuran, Metal Based Drugs 8 (2002) 263–
267.
[14] M.P. López-Gresa, R. Ortiz, L. Perelló, J. Latorre, M. Liu-González, S. García-
Granda, M. Pérez-Priede, E. Cantón, J. Inorg. Biochem. 92 (2002) 65–74.
[15] J.R. Anacona, C. Toledo, Trans. Met. Chem. 26 (2001) 228–231.
[16] I. Turel, L. Golic, P. Bukovec, M. Gubina, J. Inorg. Biochem. 71 (1998) 53–
60.
[17] I. Turel, I. Leban, N. Bukovec, J. Inorg. Biochem. 66 (1997) 241–245.
[18] Z.F. Chen, R.G. Xiong, J. Zhang, X.T. Chen, Z.L. Xue, X.Z. You, Inorg. Chem. 40
(2001) 4075–4077.
[19] L.M.M. Vieira, M.V. de Almeida, H.A. de Abreu, H.A. Duarte, R.M. Grazul, A.P.S.
Fontes, Inorg. Chim. Acta 362 (2009) 2060–2064.
[20] I. Sakiyan, E. Logoglu, S. Arslan, N. Sari, Biometals 17 (2004) 115–120.
[21] P. Skehan, R. Storeng, J. Natl. Cancer Inst. 42 (1990) 1107–1112.
[22] M.M. Abd-Elzaher, J. Chin. Chem. Soc. 48 (2001) 153–158.
100 lg/ml (Fig. 7).
[23] G.G. Mohamed, N.E.A. El-Gamel, Spectrochim. Acta
r3154.
A 60 (2004) 3141–
6. Conclusion
[24] L.M.M. Vieira, M.V. de Almeida, M.C.S. Lourenço, F.A.F.M. Bezerra, A.P.S. Fontes,
Eur. J. Med. Chem. 44 (2009) 4107–4111.
[25] V.L. Dorofeev, Chem. Acta 38 (2004) 45–49.
[26] S. Kumar, A. Rai, S.B. Rai, D.K. Rai, A.N. Singh, V.B. Singh, J. Mol. Struct. 791
(2006) 23–29.
[27] M.S. Refat, G.G. Mohamed, R.F. de Farias, A.K. Powell, M.S. El-Garib, S.A. El-
Korashy, M.A. Hussien, J. Therm. Anal. Calor. 102 (2010) 225–232.
[28] M.S. Refat, G.G. Mohamed, J. Chem. Eng. Data 55 (2010) 3239–3246.
[29] S. Kasselouri, N. Hadjiliadis, Inorg. Chim. Acta 168 (1990) 15.
[30] L.J. Bellamy, The Infrared Spectra of Complex Molecules, third ed., Chapman
and Hall, London, 1975.
[31] K. Nakamoto, Infrared Spectra of Inorganic and Coordination Compounds, New
York, Wiley Interscience, 1970.
[32] F.A. Cotton, G. Wilkinson, C.A. Murillo, M. Bochmann, Advanced Inorganic
Chemistry, sixth ed., Wiley, New York, 1999.
The lomefloxacin drug (LFX) and its transition metal complexes
with glycine have been prepared and fully characterized using the
different spectral and physicochemical studies. The LFX drug has
several coordinating sites which are suitably spatially arranged
to bind transition metals which require hexa-coordination and gly-
cine as essential amino acid behaves as a uni-negative bidentate li-
gand with NO donor sites and coordinated to the metal ions via the
amino group N and deprotonated carboxylic oxygen. Significantly,
further investigations on their antitumor activity revealed that
such complexes possessed a considerable antitumor activity which
was thought to be related with its DNA-binding affinity. The better
binding properties of the complexes should be attributed to the
good coplanarity of the ligand after coordination with metal ions.
Meanwhile, nature of the central metal ions also affected the inter-
calative ability. Further study of complexes based on LFX as anti-
bacterial drug is ongoing in our group.
[33] H.F. Abd El-halim, M.M. Omar, G.G. Mohamed, Spectrochim. Acta A 78 (2011)
36–44.
[34] A.W. Coats, J.P. Redfern, Nature 201 (1964) 68–79.
[35] H.W. Horowitz, G.M. Jetzger, Anal. Chem. 35 (1963) 1464–1468.
[36] O.A. El-Gammal, Spectrochim. Acta A 75 (2010) 533–542.
[37] G.G. Mohamed, F.A. Nour El-Dien, A. El-Gamel, J. Therm. Anal. Calorim. 67
(2002) 135–146.
[38] G.G. Mohamed, M.H. Soliman, Spectrochim. Acta A 76 (2010) 341–347.
[39] A.N.M.A. Alaghaz, R.A. Ammar, Eur. J. Med. Chem. 45 (2010) 1314–1322.
[40] Eun-Kyoung Choi, Hye-Hyang Lee, Mi-Sun Kang, Byung-Gook Kim, Hoi-Soon
Lim, Seon-Mi Kim, In-Chol Kang, J. Microbiol. 48 (2010) 40–43.
[41] J.A. Cowan, Introduction to the Biological Chemistry of Magnesium,
Magnesium in biology – Wikipedia, the Free Encyclopedia.htm, VCH, New
York, 1995.
Acknowledgments
The authors express their deep thanks to Prof. Dr. Maher M.I.
El-Dessouky, Professor of Inorganic Chemistry, Cairo University,
for revising the manuscript and his valuable comments.